Key result
Simvastatin 10 mg/day for 3 months significantly increased flow-mediated dilation from 6.12% to 10.32% and reduced hs-CRP levels by 51.6% in children with Kawasaki disease and coronary abnormalities.
Why the study?
Does simvastatin improve chronic vascular inflammation and endothelial dysfunction in children complicated with coronary arterial abnormality late after Kawasaki disease?
Population
22 children, including 11 with Kawasaki disease complicated by a history of documented coronary arterial…
Comparison
Simvastatin 10 mg oral once daily at bedtime for… vs Healthy age- and gender-matched controls who did…
Design
Cohort, All measurements for FMD were performed by the same operator who was…
Follow-up
3 months
Authors
Loading...
May support simvastatin for endothelial function in post-Kawasaki children with coronary abnormalities; hypothesis-generating, needs randomized confirmation.
Does simvastatin improve chronic vascular inflammation and endothelial dysfunction in children complicated with coronary arterial abnormality late after Kawasaki disease?
Absolute Event Rate: 10.32% vs 6.12%
p-value: p=<0.001
Short-term simvastatin therapy significantly improves chronic vascular inflammation and endothelial dysfunction in children with coronary arterial abnormalities late after Kawasaki disease.
Huang et al. (2008) studied Kawasaki disease complicated with coronary arterial abnormality (n=22). Simvastatin vs. Baseline (pre-treatment) was evaluated on Flow-mediated dilation (FMD) of the brachial artery (p=<0.001). Simvastatin 10 mg/day for 3 months significantly increased flow-mediated dilation from 6.12% to 10.32% and reduced hs-CRP levels by 51.6% in children with Kawasaki disease and coronary abnormalities.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: